E-LIB Suche - Ergebnisse für: Tougeron, D

1

Prédiction de l'expression de PD-L1 sur scanner pré-thérape..:

Zemmour, Y. ; Conze, P.H. ; Lebeau, L....
Annales de Pathologie. 44 (2024) 4 - p. 303 , 2024

Link: https://doi.org/10.1016/..

2

47P Does metastatic site influence the outcome in colorecta..:

Smolenschi, C. ; Tanguy, M-L. ; Ben Abdelghani, M....
Annals of Oncology. 35 (2024) - p. S23 , 2024

Link: https://doi.org/10.1016/..

3

395MO Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PB..:

Raymond, E. ; Xu, J. ; Kato, K....
Annals of Oncology. 35 (2024) - p. S159 , 2024

Link: https://doi.org/10.1016/..

4

3O PRODIGE 68 - UCGI 38 - SOREGATT: A randomized phase II s..:

Ducreux, M.P. ; Ben Abdelghani, M. ; Tougeron, D....
Annals of Oncology. 35 (2024) - p. S3 , 2024

Link: https://doi.org/10.1016/..

5

LBA1 Pembrolizumab in combination with xelox and bevacizuma..:

Tougeron, D. ; Emile, J.F. ; Bodere, A....
Annals of Oncology. 35 (2024) - p. S212 , 2024

Link: https://doi.org/10.1016/..

6

496TiP Randomised phase II study evaluating trifluridine/ti..:

de la Fouchardiere, C. ; Chabaud, S. ; Perrier, H....
Annals of Oncology. 35 (2024) - p. S197-S198 , 2024

Link: https://doi.org/10.1016/..

7

31P Effect of fruquintinib in patients with heavily pretrea..:

Tabernero, J. ; Eng, C. ; Lonardi, S....
Annals of Oncology. 35 (2024) - p. S15-S16 , 2024

Link: https://doi.org/10.1016/..

8

66P Targeted treatment (TT) after immune checkpoint inhibit..:

Ambrosini, M. ; Tougeron, D. ; Modest, D.P....
Annals of Oncology. 35 (2024) - p. S32 , 2024

Link: https://doi.org/10.1016/..

9

Prediction of response to immune checkpoint blockade in pat..:

Ratovomanana, T. ; Nicolle, R. ; Cohen, R....
Annals of Oncology. 34 (2023) 8 - p. 703-713 , 2023

Link: https://doi.org/10.1016/..

10

OC-0277 Capecitabine or 5-fluorouracil infusion with radiot..:

Delhiat, A. ; Lemanski, C. ; Le-Malicot, K....
Radiotherapy and Oncology. 182 (2023) - p. S211-S212 , 2023

Link: https://doi.org/10.1016/..

11

139P Genomic prognostic and potential theragnostic factors ..:

Hamza, A. ; Masliah-Planchon, J. ; Neuzillet, C....
ESMO Open. 8 (2023) 1 - p. 101989 , 2023

Link: https://doi.org/10.1016/..

12

Long term activity of vemurafenib in cancers with BRAF muta..:

Blay, J.Y. ; Cropet, C. ; Mansard, S....
ESMO Open. 8 (2023) 6 - p. 102038 , 2023

Link: https://doi.org/10.1016/..

13

CO170 Treatment Exposure-Adjusted Event Rates (EAERs) for G..:

Howe, A. ; Hernandez, L.G. ; Paly, V....
Value in Health. 26 (2023) 12 - p. S44-S45 , 2023

Link: https://doi.org/10.1016/..

14

Esophageal cancer - French intergroup clinical practice gui..:

Veziant, Julie ; Bouché, Olivier ; Aparicio, T....
Digestive and Liver Disease. 55 (2023) 12 - p. 1583-1601 , 2023

Link: https://doi.org/10.1016/..

15

Efficacy of immunotherapy in mismatch repair-deficient adva..:

Alouani, E. ; Mercier, M. ; Flecchia, C....
ESMO Open. 8 (2023) 3 - p. 101574 , 2023

Link: https://doi.org/10.1016/..